SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2— Dosing initiated in Cohort 2 of the registrational study; topline single-ascending-dose data expected in the first half of 2027 —HUNTSVILLE, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Serina Ther…

SER

Related stories